Compare Raymond James Financial, Inc. (RJF) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Summit Therapeutics Inc — how do they compare? Raymond James Financial, Inc. trades at $157.94 (market cap $30.51B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Raymond James Financial, Inc. is far larger — about 2.2× Summit Therapeutics Inc's market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 75 Days and Summit Therapeutics Inc for 16 Days on average.
| RJF | SMMT | |
|---|---|---|
Market Cap | $30.51B | $13.71B |
Volume | 1,206,253 | 6,173,057 |
Sector | Financials | Health |
52-Week High | $181.18 | $26.38 |
52-Week Low | $140.89 | $12.43 |
Typical Hold Time | 75 Days | 16 Days |
Enterprise Value | $24.37B | $13.04B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $159.04, up 1.11% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.14 surpassing the $2.93 estimate. Revenue has grown steadily from $10.9B in 2022 to $13.84B in 2025, while net income reached $2.14B. A quarterly dividend of $0.54 was declared, payable in October 2026.
The outlook is supported by solid fundamentals, including a P/E of 13.83 and ROE of 18.48%, but risks include volatile cash flows from investing activities and rising expenses. Analysts are neutral with a consensus price target of $184.00, implying potential upside. Investor sentiment is mixed amid recent institutional buying and selling activity.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
